Prospective Study on Neoadjuvant Treatments for Locally Advanced Rectal Cancer with prediction TRG3

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2500096607

Enrollment

Unknown

Registered

2025-01-26

Start date

2025-02-05

Completion date

Unknown

Last updated

2025-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Locally advanced rectal cancer

Interventions

FOWARC :The FOWARC regimen (mFOLFOX6 for 5 cycles + radiotherapy at 46-50.4 Gy) recommended by the CSCO guidelines.

nCRT:Radiotherapy (2 Gy each time, 25 sessions) + concurrent oral capecitabine (1.0 g, po, bid)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1)Sufficient clinical features, imaging, colonoscopy and other data are available for the prediction model. (2)LARC patients with prediction TRG 3. (3)The primary rectal cancer lesion is expected to be resectable. (4)Informed consent has been obtained for participation in the study.

Exclusion criteria

Exclusion criteria: (1) Patients for whom the efficacy of neoadjuvant therapy could not be evaluated; (2) Refused any of the neoadjuvant treatment regimens provided in this study during the research process; (3) Refused to participate in the study or withdrew from it midway.

Design outcomes

Primary

Measure	Time frame
Pathologic complete response, pCR;Postoperative intestinal function score (e.g. LARS score);	—

Secondary

Measure	Time frame
Tumor regression grading,TRG;Acute toxic reaction;	—

Countries

China

Contacts

Public ContactWang Xiaodong

West China Hospital, Sichuan University

wangxiaodong@wchscu.cn+86 189 8060 6164

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026